Biofrontera Inc Warrants (27/10/2026) BFRIW 深 沪
等待开盘 03-26 09:30:00 美东时间
0.0403
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 0.0403
- 总市值 0
- 52周最高 0.277
- 市盈率 静 --
- 换手率 NaN.00%
- 52周最低 0.0251
- 委 比 -99.83%
- 总股本 --
- 历史最高 9.18
- 量 比 0
- 振 幅 0.00%
- 历史最低 0.005
- 每 手 1
- 风险率 0.03%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Biofrontera Earnings Call: Profits Rise, Risks Remain
Biofrontera, Inc. (($BFRI)) has held its Q4 earnings call. Read on for the main...
03-20 08:09
Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.20 by 146.15 percent. This is a 352.63 percent increase over losses of $(0.19) per share from the
03-20 05:49
Biofrontera reports rise in Q4 revenue, turns profitable
Biofrontera (BFRI) reported record Q4 2025 revenue of $17.1M, up 36% year-over-year. Gross margin surged to 82.4%, driven by improved cost structure after its transaction with Biofrontera AG. The comp...
03-20 03:18
Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength
Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength Overview US biopharma firm's Q4 revenue rose 36% yr/yr to record high, driven by Ameluz sales Company posted Q4 net income of $5.6 mln, reversing prior-year loss Gross margin improved to 82.4% in Q4, reflecting lo
03-19 21:36
BRIEF-Biofrontera Q4 Revenue USD 17.1 Million
BRIEF-Biofrontera Q4 Revenue USD 17.1 Million Mar 19 (Reuters) - Biofrontera Q4 net income USD 5.6 million. Q4 adjusted EBITDA USD 4.9 million Q4 operating expenses USD 12.5 million
03-19 21:25
Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million
Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million Biofrontera published a financial results press release reporting record Q4 and FY 2025 results and a business update. Q4 revenue rose 36% to USD 17.1 million, while gross margin expanded 24.
03-19 21:25
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Biofrontera Reports Positive Phase 2b Acne Trial Results
An announcement from Biofrontera ( ($BFRI) ) is now available. On March 9, 2026...
03-09 21:49
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
Biofrontera Inc. announced positive results from its Phase 2b clinical trial of Ameluz® PDT for moderate to severe acne vulgaris. The 3-hour incubation regimen showed superior efficacy, reducing inflammatory lesions by 57.97% vs. 36.51% with vehicle. Safety and tolerability were favorable, with most adverse events mild to moderate. Patient satisfaction was high, with 85.7% willing to undergo PDT again. Acne vulgaris presents a promising new indic...
03-09 13:15
Biofrontera Announces US Patent Trial And Appeal Board Final Written Decision Finding All Challenged Claims Of Sun Pharma's '028 Patent To Be Unpatentable
Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy ("PDT"), today announced that on February 23, 2026, the U.S. Patent Trial and
02-26 22:20
